ReviewInflammatory bowel diseases2016
Reversibility of Stricturing Crohn's Disease-Fact or Fiction?
Review in Inflammatory bowel diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Fibrosis: cross-organ biology and pathways to development of innovative drugs.Nature reviews. Drug discovery · 2025Review
- Article
- Gene and protein expression of epithelial to mesenchymal transition for intestinal and anal fistula: a systematic review.Annals of coloproctology · 2023Review
- Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.Alimentary pharmacology & therapeutics · 2022Article
- Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation.Journal of Crohn's & colitis · 2022Article
- Article
- Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.Expert review of gastroenterology & hepatology · 2021Review
- A polymeric diet rich in transforming growth factor beta 2 does not reduce inflammation in chronic 2,4,6-trinitrobenzene sulfonic acid colitis in pre-pubertal rats.BMC gastroenterology · 2020Article
- Fibrostenotic strictures in Crohn's disease.Intestinal research · 2020Review
- Endoplasmic Reticulum Stress in Subepithelial Myofibroblasts Increases the TGF-β1 Activity That Regulates Fibrosis in Crohn's Disease.Inflammatory bowel diseases · 2020Article
- Pathology of Fibrosis in Crohn's Disease-Contribution to Understanding Its Pathogenesis.Frontiers in medicine · 2020Article
- Intestinal stenosis in Crohn's disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets.Therapeutic advances in gastroenterology · 2020Article
- The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis.Journal of Crohn's & colitis · 2019Article
- Strictureplasty in Complex Crohn's Disease: Beyond the Basics.Clinics in colon and rectal surgery · 2019Review
- IL-17A Promotes Initiation and Development of Intestinal Fibrosis Through EMT.Digestive diseases and sciences · 2018Article
- Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease.Journal of Crohn's & colitis · 2018Article
- Intestinal fibrosis: ready to be reversed.Current opinion in gastroenterology · 2017Review
- Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.BMC gastroenterology · 2017Article
- Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective.Scientific reports · 2017Article
- Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.Gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Intestinal fibrosis is a common feature of Crohn's disease and may appear as a stricture, stenosis, or intestinal obstruction. Fibrostenosing Crohn's disease leads to a significantly impaired quality of life in affected patients and constitutes a challenging treatment situation. In the absence of specific medical antifibrotic treatment options, endoscopic or surgical therapy approaches with their potential harmful side effects are frequently used. However, our understanding of mechanisms of fibrogenesis in general and specifically intestinal fibrosis has emerged. Progression of fibrosis in the liver, lung, or skin can be halted or even reversed, and possible treatment targets have been identified. In face of this observation and given the fact that fibrotic alterations in various organs of the human body share distinct core characteristics, this article aims to address whether reversibility of intestinal fibrosis may be conceivable and to highlight promising research avenues and therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.